Healthcare provider profile · identity verified

Jesse Lyon, M.D.

Internal Medicine · LA MESA, CA · NPI 1124393210

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	966	327
Rosuvastatin Calcium	Rosuvastatin Calcium	532	184
Losartan Potassium	Losartan Potassium	457	157
Metformin Hcl Er	Metformin Hcl	411	145
Amlodipine Besylate	Amlodipine Besylate	409	141
Lisinopril	Lisinopril	407	140
Levothyroxine Sodium	Levothyroxine Sodium	348	106
Omeprazole	Omeprazole	253	105
Terazosin Hcl	Terazosin Hcl	237	71
Gabapentin	Gabapentin	220	91
Meloxicam	Meloxicam	214	80
Hydrochlorothiazide	Hydrochlorothiazide	195	64
Metformin Hcl	Metformin Hcl	191	59
Metoprolol Tartrate	Metoprolol Tartrate	191	61
Sertraline Hcl	Sertraline Hcl	188	66
Albuterol Sulfate Hfa	Albuterol Sulfate	186	83
Atenolol	Atenolol	163	53
Glipizide	Glipizide	163	62
Tamsulosin Hcl	Tamsulosin Hcl	157	54
Pradaxa	Dabigatran Etexilate Mesylate	153	49
Trazodone Hcl	Trazodone Hcl	138	53
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	136	43
Furosemide	Furosemide	131	43
Pantoprazole Sodium	Pantoprazole Sodium	130	37
Alendronate Sodium	Alendronate Sodium	124	37
Finasteride	Finasteride	113	38
Potassium Chloride	Potassium Chloride	101	45
Allopurinol	Allopurinol	100	32
Mirtazapine	Mirtazapine	95	35
Triamcinolone Acetonide	Triamcinolone Acetonide	90	54
Jardiance	Empagliflozin	88	29
Metoprolol Succinate	Metoprolol Succinate	80	24
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	73	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	26
Famotidine	Famotidine	68	27
Duloxetine Hcl	Duloxetine Hcl	63	31
Alvesco	Ciclesonide	61	28
Donepezil Hcl	Donepezil Hcl	60	19
Propranolol Hcl	Propranolol Hcl	59	15
Simvastatin	Simvastatin	55	22
Colchicine	Colchicine	54	16
Ciclopirox	Ciclopirox	52	29
Azelastine Hcl	Azelastine Hcl	51	13
Bupropion Xl	Bupropion Hcl	51	24
Acyclovir	Acyclovir	50	23
Clopidogrel	Clopidogrel Bisulfate	47	16
Spiriva Respimat	Tiotropium Bromide	47	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	46	18
Prednisone	Prednisone	44	41
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	43	12
Memantine Hcl	Memantine Hcl	42	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	41	22
Ezetimibe	Ezetimibe	41	13
Ibuprofen	Ibuprofen	41	21
Hydralazine Hcl	Hydralazine Hcl	40	16
Estradiol	Estradiol	39	15
Fluoxetine Hcl	Fluoxetine Hcl	38	14
Ondansetron Odt	Ondansetron	38	18
Spironolactone	Spironolactone	38	15
Humulin N Kwikpen	Insulin Nph Human Isophane	37	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	35	35
Arexvy	Rsvpref3 Antigen/As01e/Pf	35	35
Hydroxyzine Hcl	Hydroxyzine Hcl	35	suppressed
Carvedilol	Carvedilol	34	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	34	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	32
Eliquis	Apixaban	33	11
Humulin N	Insulin Nph Human Isophane	33	suppressed
Lovastatin	Lovastatin	31	suppressed
Warfarin Sodium	Warfarin Sodium	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	11
Hydrocortisone	Hydrocortisone	30	17
Montelukast Sodium	Montelukast Sodium	28	suppressed
Trospium Chloride	Trospium Chloride	28	suppressed
Breyna	Budesonide/Formoterol Fumarate	27	suppressed
Fluconazole	Fluconazole	27	suppressed
Naproxen	Naproxen	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	13
Midodrine Hcl	Midodrine Hcl	23	suppressed
Nitroglycerin	Nitroglycerin	23	11
Amoxicillin	Amoxicillin	22	16
Doxycycline Monohydrate	Doxycycline Monohydrate	22	16
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	22	11
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	19	17
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	19	11
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Metronidazole	Metronidazole	18	11
Ozempic	Semaglutide	18	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Cartia Xt	Diltiazem Hcl	17	12
Mupirocin	Mupirocin	17	suppressed
Naltrexone Hcl	Naltrexone Hcl	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Topiramate	Topiramate	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Cefadroxil	Cefadroxil	16	15
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Cephalexin	Cephalexin	15	13
Fluocinonide	Fluocinonide	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Ofloxacin	Ofloxacin	14	suppressed
Carbamazepine	Carbamazepine	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Digoxin	Digoxin	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Nystatin	Nystatin	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Fluocinolone Acetonide	Fluocinolone/Shower Cap	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error